Research Labs

The Antonsecu lab focuses on translocation-associated sarcoma pathogenesis and generating in vitro models.

Researcher Michael Berger focuses on massively parallel sequencing of tumor DNA for biomarker discovery and clinical diagnostics.

Physician-scientist Brett Carver focuses on the identification of molecular pathways involved in prostate cancer initiation and progression.

Physician-scientist Emily Cheng studies the molecular mechanisms of cell death and their implications in tumorigenesis, tumor-microenvironment interactions, targeted therapy, and immunotherapy.

Physician-scientist Ping Chi studies genetic and epigenetic mechanisms of transcriptional regulation by oncogenic factors in GIST, MPNST, melanoma and other solid tumors.

My research involves the elucidation of genetic and biologic insights of human malignant lymphomas. We leverage large-scale unbiased profiling including genomics, transcriptomics, proteomics to identify candidate oncogenes and proteins that are pathogenetically relevant in lymphoma. We utilize molecular technologies, human tumor tissues and patient-derived xenografts and transgenic animal models to determine the functional significance of novel genes and proteins involved in lymphoma pathogenesis. Using primary tumors as our discovery models, the overall goal of our studies is to understand novel mechanisms of oncogenesis, identify tumor biomarkers and vulnerabilities that will facilitate early detection and precision therapies that improve patient outcomes.

Physician-scientist James Fagin focuses on the pathogenesis of thyroid cancer and the role of oncogenic kinases.

Physician-scientist Katharine Hsu studies the biology of human natural killer cells and how they contribute to disease processes.

Cancer biologist and pediatric oncologist Alex Kentsis leads research in the functional proteomics and molecular pharmacology of refractory childhood cancers.